behavioral health science award  - letter of intent due july 29, 2021

independent investigator with a faculty-level appointment (or equivalent).

• letter of intent is required. an invitation to submit a full application is not required.
• supports research that span the spectrum of behavioral health science including prevention, survivorship, quality of life, and psychosocial research related to cancer.
• must address at least one of the fy21 prcrp topic areas.
• must address at least one of the fy21 prcrp military health focus areas.
• preliminary data required.
• pilot clinical trials are allowed.
• the maximum allowable funding for the entire period of performance is $1,000,000 for direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 4 years.

career development award – fellow option – letter of intent due july 29, 2021

principal investigator (pi): independent investigators at or above the level of assistant professor or instructor (or equivalent) and within 7 years after completion of their terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline.

career guide: investigators at or above the level of associate professor (or equivalent); must have a proven publication and funding record in cancer research

• letter of intent is required. an invitation to submit a full application is not required.
• supports independent, early-career investigators to conduct impactful research with the mentorship of an experienced cancer researcher.
• must address at least one of the fy21 prcrp topic areas.
• must address at least one of the fy21 prcrp military health focus areas.
• preliminary data are not required.
• clinical trials are not allowed.
• the maximum allowable funding for the entire period of performance is $400,000 for direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 3 years.

translational team science award – letter of intent due july 29, 2021

at least two, and a maximum of three, pis must partner in one overarching correlative or translational research study.

• letter of intent is required.  an invitation to submit a full application is not required.
• emphasizes multi-pi, multidisciplinary collaborations.
• supports translational studies associated with an ongoing or completed clinical trial that can lead to a future clinical trial or clinical application in cancer research.
• not intended to support high throughput screenings, sequencing, etc.
• must address at least one of the fy21 prcrp topic areas.
• must address at least one of the fy21 prcrp military health focus areas.
• preliminary data are required.
• clinical trials are allowed.
  • the maximum allowable funding for the entire period of performance is $2,500,000 for direct costs.
  • indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • the maximum period of performance is 4 years.
  • at least one of the pis is encouraged to be a military or us department of veterans affairs investigator.

idea award – preproposal due may 20, 2021

independent investigator with a faculty-level appointment (or equivalent).

• preproposal is required; application submission is by invitation only.
• supports innovative, untested, high-risk/ potentially high-reward concepts, theories, paradigms, and/or methods in cancer research.
• emphasis on innovation.
• must address at least one of the fy21 prcrp topic areas.
• must address at least one of the fy21 prcrp military health focus areas.
• preliminary data are not required.
• clinical trials are not allowed.
• the maximum allowable funding for the entire period of performance is $500,000 for direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 3 years

impact award – preproposal due may 20, 2021

independent investigators at or above the level of assistant professor (or equivalent) are eligible to submit an application.

• preproposal is required; application submission is by invitation only.
• supports hypothesis-driven, high impact research.
• encourages applications that support research projects or ideas that specifically focus on critical scientific and clinical cancer issues which, if successfully addressed, have the potential to make a near term, major impact on one of the fy21 prcrp topic areas.
• must address at least one of the fy21 prcrp topic areas.
• must address at least one of the fy21 prcrp military health focus areas.
• preliminary data are required.
• clinical trials are allowed.
• the maximum allowable funding for the entire period of performance is $1,250,000 for direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 3 years.

fy21 ocrp program announcements and general application instructions for the following award mechanism are posted on the grants.gov website.    

https://cdmrp.army.mil/funding/ocrp

omics consortium award – preapplication due june 24, 2021

must be an independent investigator at or above the level of assistant professor (or equivalent).

• supports a multi-institutional research effort conducted by leading cancer researchers and advocates that focuses on the compilation of new and/or use of existing large datasets to study the origin of ovarian cancer, with an emphasis on early detection and screening.

two options are available:

omics development award option:

• funds support assembling consortium members and laying the groundwork for the research project, including proof of concept.
• ovarian cancer advocate(s) are required on the research team.
• funded applicants will be eligible to compete for the consortium award, which will support the execution of the full research project and is anticipated to be offered in fy23, pending availability of funds.

omics consortium award option:

• the research effort will provide immediate benefits for ovarian cancer patients in initial diagnosis and therapy and the end result will lead to improvements in early detection and screening detection of ovarian cancer. 
• consortium should maximize the use of resources and minimize unnecessary duplication among consortium members by sharing resources among all consortium members.
• ovarian cancer advocate(s) are required on the research team.
• submission of a letter of intent is required prior to full application submission.

omics development award option:

• maximum funding of $400,000 for direct costs (plus indirect costs).
• maximum period of performance is 2 years.

omics consortium award option:

• maximum funding of $2.5 million for direct costs (plus indirect costs) from fy21 and future appropriations.
• maximum period of performance is 4 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the ocrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

connection grants are expected to respond to the objectives of the connection program.

these grants support events and outreach activities geared toward short-term, targeted knowledge mobilization initiatives. these events and activities represent opportunities to exchange knowledge and to engage with participants on research issues of value to them. events and outreach activities funded by a connection grant can often serve as a first step toward more comprehensive and longer-term projects.

connection grants support workshops, colloquiums, conferences, forums, summer institutes, or other events or outreach activities that facilitate:

• disciplinary and/or interdisciplinary exchanges in the social sciences and humanities;
• scholarly exchanges between those working in the social sciences and humanities and those working in other research fields;
• intersectoral exchanges between academic researchers in the social sciences and humanities and researchers and practitioners from the public, private and/or not-for-profit sectors; and/or
• international research collaboration and scholarly exchanges with researchers, 世界杯2022赛程表淘汰赛 and non-academic partners from other countries.

partnership engage grants are expected to respond to the objectives of the insight program and the connection program. however, partnership engage grants cannot respond exclusively to the objectives of the connection program.

these grants provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector. the small-scale, stakeholder-driven partnerships supported through partnership engage grants are meant to respond to immediate needs and time constraints facing organizations in non-academic sectors. in addressing an organization-specific need, challenge and/or opportunity, these partnerships let non-academic organizations and postsecondary researchers access each other’s unique knowledge, expertise and capabilities on topics of mutual interest.

sshrc welcomes applications involving indigenous research, as well as those involving research-creation.

the forest sector investment and innovation program provides funding for strategic investments in the forest sector that:

• improve productivity and innovation
• enhance competitiveness
• support new market access
• provide benefits to ontario’s broader forest sector
• strengthen regional economies

the fy21 defense appropriations act provides funding to the department of defense tick-borne disease research program (tbdrp) to support innovative, high-impact tick-borne disease research. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc). 

the fy21 tbdrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

applicants to the fy21 tbdrp funding opportunities should be relevant to one or more of the following focus areas; however an application that proposes research outside of these focus areas is acceptable, as long as the applicant provides strong justification. applicants are particularly encouraged to submit applications addressing the diagnosis and treatment focus areas.

• diagnosis

• development of direct detection diagnostic assay for agents of lyme and/or other tick-borne diseases (tbds).
• diagnostic biomarker panel for lyme disease and/or other tbds that distinguishes tick-borne (tb) infection from other febrile illnesses.
• approaches capable of distinguishing active infection and previous exposure, and/or monitoring response to treatment.
• innovative approaches that provide diagnosis for a single or multiple tb infections.

• treatment

• novel therapeutic strategies for acute and persistent tbds.
• potential treatments designed to mitigate development of long-term sequelae following infection with bacterial, parasitic, or viral tb agents.
• translational approaches that bridge basic biology to the development of potential treatments.

• prevention

• drugs, antibodies, vaccines, or other novel approaches that can be administered and/or utilized prophylactically to prevent human tbd.
• identification, validation, and/or improvement of tick- or reservoir-targeted prevention and control interventions that are safe and non-toxic to non-target species.
• understanding the ecology of understudied tbd vectors and reservoirs with emphasis on how it relates to human risk.

• pathogenesis

• pathogenesis of persistent clinical manifestations associated with lyme disease.
• immune evasion and/or tolerance of tb pathogens (lyme and/or other tbds).
• effects of tick sialome on human infection, immune response, disease progression, and pathogen dissemination.
• tb infections and co-infections (simultaneous or sequential) and their effects on human disease severity, the local and systemic immune response, or pathogen synergy and competition.
• pathogenesis of mammalian meat allergy (allergic response to galactose-alpha-1,3-galactose (alpha-gal)).
• understanding the potential role of maternal-fetal transmission and the ability to prevent tbds by this mode of transmission.

https://cdmrp.army.mil/funding/tbdrp

career development award – preproposal due may 26, 2021

principal investigator (pi):

early-career research scientist, physician scientist, or other qualified clinical scientist, within 10 years of completion of his/her terminal degree (excluding time spent in residency or on family medical leave) at the time of the submission, working to become independent investigators who exhibit a strong desire to pursue careers in tick-borne disease research; time spent as a postdoctoral fellow is not excluded

mentor: independent investigators at or above the level of associate professor (or equivalent); must have a recent (last 5 years), proven funding and publication record in tick-borne disease research. .

the pi and mentor do not need to be located within the same organization.

• to fund early-career investigators to conduct impactful research under the mentorship of an experienced tick-borne disease researcher.
• career development plan is required. plan should be prepared with appropriate guidance from the mentor, should clearly articulate a strategy for acquiring the necessary skills, competence, and expertise to establish a career at the forefront of tick-borne disease research, and should outline how the pi will gain experience in tick-borne disease research. pi’s institution must demonstrate a commitment to the pi through a minimum of 75% protected research time for tick-borne disease research. the application must include clearly stated plans for interactions and communication coordination between the pi and mentor.
• preliminary data is encouraged, but not required.
• clinical trials are not allowed.
• maximum funding of $300k for direct costs (plus indirect costs).
• maximum period of performance is 3 years.

idea development award – preproposal due may 26, 2021

independent investigators at or above the level of assistant professor (or equivalent).

• to fund research that could lead to impactful discoveries or major advancements that will accelerate progress in improving outcomes for individuals affected by lyme diseases and/or other  tick-borne illnesses.
• research should be conceptually innovative, exhibit high levels of creativity, or challenge existing research paradigms.
• applications must describe the short- and long-term impact of the proposed research, as well as the public health burden of the diseases being addressed.
• preliminary data is encouraged, but not required.
• clinical trials are not allowed; human studies/clinical research are permitted.
• preproposal is required; application submission is by invitation only.

• maximum funding of $600k for direct costs (plus indirect costs).
• maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website. the application package containing the required forms for each award mechanism will also be found on grants.gov. a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.  

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org. for more information about the tbdrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507
help@ebrap.org

the fy21 defense appropriations act is anticipated to provide funding to the department of defense arp to support research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders (asd).  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate, manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

fy21 arp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.    

https://cdmrp.army.mil/funding/arp

clinical trial award – preproposal due may 3, 2021

investigators at or above the level of assistant professor (or equivalent) or

nested early-career investigator partnering principal investigator (pi) option: investigators at or above the level of assistant professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) that meets the following criteria at the application submission deadline date:

• must be in a current postdoctoral training position or have completed postdoctoral training by the application deadline
• is no more than 7 years from the receipt of a terminal degree
  • has the freedom to commit at least 50% time to the project
  • supports research with the potential to have a major impact on the treatment and/or management of autism spectrum disorders (asd).
  • preliminary data relevant to the proposed clinical trial are required.
  • early-career investigator partnering pi option supports the development of young investigators pursuing or wishing to pursue a career in asd clinical trial research.
  • pre-application is required; application submission is by invitation only.
• the maximum allowable funding for the entire period of performance is $1,800,000 for direct costs (plus indirect costs).
• the maximum period of performance is 4 years.

early-career investigator partnering pi option:

• the maximum allowable funding for the entire period of performance is $2,100,000 for direct costs (plus indirect costs).
• the maximum period of performance is 4 years.

clinical translational research award – preproposal due may 3, 2021

investigators at or above the level of assistant professor (or equivalent)

• supports early-phase, proof-of-principle translational studies with the potential to have a major impact on the treatment and/or management of asd.
• preliminary data relevant to the proposed project are required.
• pre-application is required; application submission is by invitation only.
• the maximum allowable funding for the entire period of performance is $600,000 for direct costs (plus indirect costs).
• the maximum period of performance is 3 years.

idea development award – preproposal due may 3, 2021

investigators at or above the level of assistant professor (or equivalent)

• multiple pi option:  
  up to two investigators may collaborate on a single application, each of whom will be recognized as a pi and receive a separate award.
• supports the development of innovative, high-impact ideas that advance the understanding of asd and ultimately lead to improved outcomes.
• preliminary data are required.
• multiple pi option: up to two investigators may collaborate on a single application, each of whom will be recognized as a pi and receive a separate award.
• pre-application is required; application submission is by invitation only.
• the maximum allowable funding for the entire period of performance is $550,000 for direct costs (plus indirect costs).
• for multiple pis, the combined funding for all pis for the entire period of performance may not exceed $550,000 in direct costs (plus indirect costs).
• the maximum period of performance is 3 years.

career development award – preproposal due may 3, 2021

independent investigators at or below the level of assistant professor (or equivalent) or

established independent investigators in an area other than asd at or above the level of assistant professor (or equivalent) and seeking to transition to a career in asd, thereby bringing their expertise to the field

investigators must not have received a career development award (or equivalent) previously from any program within the cdmrp.

investigators must not have received more than $300,000 in total direct costs for previous or concurrent asd research as a principal investigator of one or more federally or privately funded, non-mentored, peer-reviewed grants.

• supports early-career, independent investigators and/or the transition of established investigators from other research fields to conduct:

○         innovative, high-impact ideas or

○         early-phase, proof-of-principle clinical trials with the potential to have a major impact on asd.

• preliminary data relevant to the proposed project are required.
• pre-application is required; application submission is by invitation only.
• the maximum allowable funding for the entire period of performance is $500,000 for direct costs (plus indirect costs).
• the maximum period of performance is 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the arp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507 
help@ebrap.org

in this call for applications, we seek to support hypothesis-driven, mechanistic research projects that explore the role played by inflammatory and immune processes in neural development and their effects on the pathophysiology of neurodevelopmental disorders (ndds). our long-term vision is that discoveries made possible by this rfa could lead to the development of mechanism-based interventions that address the fundamental molecular and physiological features that underlie neurodevelopmental conditions.

canada’s international development research centre (idrc) is pleased to announce a new funding opportunity to advance gender analysis and women’s leadership in science, technology, engineering, and mathematics (stem) fields through the gender in stem research initiative.

in the last decade, pioneering work by a number of scholars and organizations around the world has increased awareness of the importance of a more inclusive approach to science, in particular one that integrates women as scientists and users of science, and that recognizes gender analysis as integral to high-quality research and innovation. several initiatives have been launched in response, and some advances have been made. nonetheless we continue to observe twin deficits in women’s representation as leaders in science — notably, in natural sciences, and engineering and maths — and in the integration of gender analysis[1] in these fields. this requires a redoubling of efforts to deepen understanding about the twin gender deficits in stem and propose evidence-based strategies for how higher education and science systems can respond.

this initiative, therefore, will support university-led consortia to expand and deepen scholarship in low- and middle-income countries (lmics), particularly in africa, on the challenges and opportunities that women scientists experience in stem fields and on the importance of gender analysis in stem research. the initiative will increase localized evidence on the key factors that constrain or support women scientists and gender analysis in stem at different levels and in different stem domains, on actual or potential strategies (structures, programs and policies) to address these, and on lessons learned at the level of universities and responsible ministries, nationally and regionally. through research, consortia will be expected to identify innovative approaches that increase the capacity of universities and other higher-education institutions to be more inclusive of women and gender analysis in stem. the ultimate objective is to increase the contribution of science to gender equality.

expressions of interest (eois) are invited from research consortia that bring together the range of multi-disciplinary and sectoral perspectives, capacities, and contributions needed to undertake gender in stem research in line with the objectives, outcomes, and themes of this funding opportunity, as set out below.

eligibility considerations: applications are eligible from consortia involving at least two public universities based in at least two eligible lmics. consortia may also involve researchers based at other institutions in these and other countries, and other stakeholders, as appropriate. consistent with the focus of the call, we expect women scientists to play a leading role in the consortia as established and emerging researchers.  

geographic focus: africa, asia, latin america and the caribbean. up to eight consortia may be funded, half being in africa.

duration of research grants: 36 months

budget: ca$1 million to ca$1.25 million per research consortium; a total of ca$8 million is available for this call.